Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.

---

Reif A., ANIL YAĞCIOĞLU A. E., Luts A., Messer T., Nielsen R., Buyze J., ...Daha Fazla

31st European Congress of Psychiatry (EPA), Paris, Fransa, 25 Mart 2023, (Özet Bildiri)

• Yayın Türü: Bildiri / Özet Bildiri
• Basıldığı Şehir: Paris
• Basıldığı Ülke: Fransa
• Hacettepe Üniversitesi Adresli: Evet